Fosamax® Femur Facture Lawsuits
The drug injury attorneys of Seeger Weiss LLP are currently investigating claims of Fosamax® femur fractures, with the potential of filing a Fosamax® class action lawsuit on behalf of victims. Our Fosamax® lawyers are experienced in the complicated world of Fosamax® litigation, and can help you in your Fosamax® lawsuit. Contact us using the form to the right, and a Fosamax® lawyer will review your case for free.
For over a decade, the lawyers of Seeger Weiss LLP have been representing victims of debilitating drug injuries. Our victories include a $25.16 million verdict on behalf of a young man who developed inflammatory bowel disease as a result of taking Accutane, and a $4.85 billion settlement on behalf of a class of Vioxx users who experienced heart attacks and strokes. Our leading roles in both of these cases and many others have earned us several distinctions in the legal community, including the recent title of “First Tier New York City Mass Tort Litigation and Class Action Plaintiffs’ Firm” from U.S. News and World Report’s “Best Law Firms” publication.
Seeger Weiss LLP has also been at the forefront of Fosamax® litigation since Fosamax® lawsuits first began emerging two years ago. Our Fosamax® lawyers have been so influential in the recent wave of Fosamax® class action lawsuits that two of the firm’s partners, Christopher Seeger and David Buchanan were asked to head a national forum on Fosamax®-induced femur fractures litigation earlier this year. The Fosamax® lawyers of Seeger Weiss LLP can use their expertise to help you as well. Contact us today to have one review your case for free.
A History of Fosamax® Litigation
Fosamax®, a popular drug in the bisphosphonate class of medications, is prescribed for the treatment of osteoporosis. The drug is purported to strengthen bones in women over 40, however strong evidence has shown long-term use of Fosamax® or its generic equivalent alendronate has the opposite effect. Some women who are taking the drug for five years or more have experienced atypical femur fractures during normal everyday activities without apparent cause.
The femur bone is one of the largest and strongest bones in the body known to withstand most any jolt. Common causes of femur fractures are falls, car accidents, or severe osteoporosis. A patient faithfully following doctor’s orders and taking Fosamax® is completely unaware of the side effects that may occur. The thighbones eventually become brittle and fracture easily. Unfortunately, the popularity of the drug increased to such a degree doctors began prescribing it to women who had not experienced any signs of osteoporosis but were simply at risk.
In 2008, the FDA pressured Merck the company that manufactures Fosamax® about constant reports of femur fractures. After more than a year, Merck politely responded by adding femur fractures to the list of possible side effects of the drug. Nevertheless, these important concerns were never fully disclosed to the public or to doctors who continue prescribing the drug to combat the effects of osteoporosis.
Studies published in the Journal of Orthopedic Trauma and the Journal of Bone and Mineral Research both link Fosamax® and all bisphosphonate drugs to a rare type of spontaneous fracture in the femur. These observational studies looked at patients who experienced “low-energy” femur fractures, which occur when someone falls from a standing height or less. The results were similar: patients who were taking Fosamax® on average for four years or more and those not taking Fosamax® had similar numbers of atypical subtrochanteric femur fractures mirroring classical osteoporotic hip fractures.
Bisphosphonates, or equivalents of Fosamax®, are strongly recommended for menopausal women though there is a lack of research about how long to take it. Yes, they are super drugs that prevent hip fractures and life-altering circumstances, however extended use of Fosamax® in some women may actually affect their ability to regenerate new bone and develop increased risk of fractures.
In 2010, the FDA could no longer dismiss published reports about the risks of Fosamax®. They began working closely with experts from the American Society of Bone and Mineral Research Subtrochanteric Femoral Fracture Task Force, to gather additional information that promised to provide insight into the grave risks associated with the drug. As a result, updated FDA recommendations are now available for healthcare professionals as well as patients about the possible risks and side effects of oral bisphosphonates based on mounting results of clinical trials and ongoing studies.
In conclusion, legal experts agree that as more patients become knowledgeable about Fosamax® and spontaneous femur fractures caused by long-term use of the medication, Fosamax® fracture lawsuits are likely to increase exponentially.
The U.S. Environmental Protection Agency (EPA) accused Fiat Chrysler of installing software on over 100,000 trucks and SUVs that underreported the amount of pollutants the vehicles spewed into the [...]January 12, 2017 By: Seeger Weiss read more